Aktis Oncology Statistics
Total Valuation
Aktis Oncology has a market cap or net worth of $932.80 million. The enterprise value is $698.44 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aktis Oncology has 52.52 million shares outstanding. The number of shares has increased by 53.35% in one year.
| Current Share Class | 50.65M |
| Shares Outstanding | 52.52M |
| Shares Change (YoY) | +53.35% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.44% |
| Owned by Institutions (%) | 4.63% |
| Float | 23.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.53 |
| Forward PS | 277.12 |
| PB Ratio | 4.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 125.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.27, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.27 |
| Quick Ratio | 9.18 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.50% and return on invested capital (ROIC) is -18.92%.
| Return on Equity (ROE) | -26.50% |
| Return on Assets (ROA) | -14.80% |
| Return on Invested Capital (ROIC) | -18.92% |
| Return on Capital Employed (ROCE) | -28.93% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $73,158 |
| Profits Per Employee | -$798,013 |
| Employee Count | 76 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 35.87 |
| Average Volume (20 Days) | 275,463 |
Short Selling Information
The latest short interest is 195,957, so 0.37% of the outstanding shares have been sold short.
| Short Interest | 195,957 |
| Short Previous Month | 46,658 |
| Short % of Shares Out | 0.37% |
| Short % of Float | 0.83% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aktis Oncology had revenue of $5.56 million and -$60.65 million in losses. Loss per share was -$76.44.
| Revenue | 5.56M |
| Gross Profit | -58.00M |
| Operating Income | -72.94M |
| Pretax Income | -60.65M |
| Net Income | -60.65M |
| EBITDA | -70.87M |
| EBIT | -72.94M |
| Loss Per Share | -$76.44 |
Full Income StatementBalance Sheet
The company has $246.22 million in cash and $11.87 million in debt, with a net cash position of $234.36 million or $4.46 per share.
| Cash & Cash Equivalents | 246.22M |
| Total Debt | 11.87M |
| Net Cash | 234.36M |
| Net Cash Per Share | $4.46 |
| Equity (Book Value) | 201.02M |
| Book Value Per Share | -162.43 |
| Working Capital | 222.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$61.69 million and capital expenditures -$7.66 million, giving a free cash flow of -$69.34 million.
| Operating Cash Flow | -61.69M |
| Capital Expenditures | -7.66M |
| Free Cash Flow | -69.34M |
| FCF Per Share | -$1.32 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,311.94% |
| Pretax Margin | -1,090.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aktis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.35% |
| Shareholder Yield | -53.35% |
| Earnings Yield | -6.50% |
| FCF Yield | -7.43% |
Analyst Forecast
The average price target for Aktis Oncology is $30.00, which is 68.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.00 |
| Price Target Difference | 68.92% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aktis Oncology has an Altman Z-Score of -0.6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.6 |
| Piotroski F-Score | n/a |
